Obigen Pharma Inc. (TPEX:7876)

Taiwan · Delayed Price · Currency is TWD

37.70

+0.30 (0.80%)

At close: Sep 7, 2026

Obigen Pharma Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Selling, General & Admin	60.22	52.95	48.6	43.17	22.95
Research & Development	364.56	286.85	239.14	211.7	196.16
Operating Expenses	424.78	339.8	287.74	254.87	219.11
Operating Income	-424.78	-339.8	-287.74	-254.87	-219.11
Interest Expense	-1.4	-1.72	-2	-1.62	-0.96
Interest & Investment Income	7.49	9.47	11.85	10.86	0.73
Currency Exchange Gain (Loss)	0.03	0.05	0.05	0.09	0.03
Other Non Operating Income (Expenses)	5.18	6.04	3.54	0.24	1.11
Pretax Income	-414.33	-325.96	-274.31	-245.29	-218.21
Net Income	-414.33	-325.96	-274.31	-245.29	-218.21
Net Income to Common	-414.33	-325.96	-274.31	-245.29	-218.21
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	107	106	106	102	76
Shares Outstanding (Diluted)	107	106	106	102	76
Shares Change	0.75%	0.22%	3.45%	34.82%	-
EPS (Basic)	-3.88	-3.07	-2.59	-2.39	-2.87
EPS (Diluted)	-3.88	-3.07	-2.59	-2.39	-2.87
EPS Growth	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Free Cash Flow	-335.84	-248.98	-168.76	-127.59	-278.7
Free Cash Flow Per Share	-3.15	-2.34	-1.59	-1.25	-3.67
EBITDA	-325.91	-240.53	-191.13	-160.46	-125.33
D&A For EBITDA	98.86	99.27	96.6	94.41	93.77
EBIT	-424.78	-339.8	-287.74	-254.87	-219.11